Glucagonoma staging: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 11: | Line 11: | ||
{| class="wikitable" | {| class="wikitable" | ||
! style="font-weight: bold;" | T | ! style="font-weight: bold;" | T | ||
! style="text-align: center; font-weight: bold;" | Primary Tumor | ! style="text-align: center; font-weight: bold;" | [[Primary Tumor]] | ||
|- | |- | ||
| style="font-weight: bold;" | Tx | | style="font-weight: bold;" | Tx | ||
| Line 20: | Line 20: | ||
|- | |- | ||
| style="font-weight: bold;" | Tis | | style="font-weight: bold;" | Tis | ||
| style="text-align: center;" | Carcinoma in situ | | style="text-align: center;" | [[Carcinoma in situ]] | ||
|- | |- | ||
| style="font-weight: bold;" | T1 | | style="font-weight: bold;" | T1 | ||
| style="text-align: center;" | Tumor limited to the pancreas, ≤2 cm in greatest dimension | | style="text-align: center;" | Tumor limited to the [[pancreas]], ≤2 cm in greatest dimension | ||
|- | |- | ||
| style="font-weight: bold;" | T2 | | style="font-weight: bold;" | T2 | ||
| style="text-align: center;" | Tumor limited to the pancreas, >2 cm in greatest dimension | | style="text-align: center;" | Tumor limited to the [[pancreas]], >2 cm in greatest dimension | ||
|- | |- | ||
| style="font-weight: bold;" | T3 | | style="font-weight: bold;" | T3 | ||
| style="text-align: center;" | Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery | | style="text-align: center;" | Tumor extends beyond the pancreas but without involvement of the celiac axis or the [[superior mesenteric artery]] | ||
|- | |- | ||
| style="font-weight: bold;" | T4 | | style="font-weight: bold;" | T4 | ||
| style="text-align: center;" | Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor) | | style="text-align: center;" | Tumor involves the celiac axis or the [[superior mesenteric artery]] (unresectable primary tumor) | ||
|} | |} | ||
Revision as of 18:18, 11 October 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma staging On the Web |
|
American Roentgen Ray Society Images of Glucagonoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D[3]
Overview
According to The American Joint Committee on Cancer (AJCC), there are four stages of glucagonoma based on the TNM staging sysytem.
Staging
According to The American Joint Committee on Cancer (AJCC), there are four stages of glucagonoma based on the TNM staging sysytem.[1][2]
TNM Classification
| T | Primary Tumor |
|---|---|
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ |
| T1 | Tumor limited to the pancreas, ≤2 cm in greatest dimension |
| T2 | Tumor limited to the pancreas, >2 cm in greatest dimension |
| T3 | Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery |
| T4 | Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor) |
| N | Regional Lymph Nodes |
|---|---|
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Regional lymph node metastasis |
| M | Distant Metastases |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis |
Anatomic Stage/Prognostic Groups
| Stage | T | N | M |
|---|---|---|---|
| 0 | Tis | N0 | M0 |
| IA | T1 | N0 | M0 |
| IB | T2 | N0 | M0 |
| IIA | T3 | N0 | M0 |
| IIB | T1 | N1 | M0 |
| T2 | N1 | M0 | |
| T3 | N1 | M0 | |
| III | T4 | Any N | M0 |
| IV | Any T | Any N | M1 |
References
- ↑ Stage Information for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors). http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq#section/_199
- ↑ Edge SB, Compton CC (2010). "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM". Ann Surg Oncol. 17 (6): 1471–4. doi:10.1245/s10434-010-0985-4. PMID 20180029.